Demands on the Clinical Core for clearly defined samples of persons with AD, related dementias, MCI, Lewy body spectrum disease, and age-matched controls have become more complex. Subject samples appropriate for one type of Investigation (e.g., a clinical treatment trial) are often not appropriate for other types of studies (e.g., case-control epidemiologic or genetic linkage analysis studies). Still others are needed for training clinicians to manage the multiple clinical problems expressed during the course of dementia. To meet these demands, the Clinical Core will continue to provide AD patients, non-AD dementia patients, MCI, and cognitively normal subjects selected for maximum appropriateness for participation in clinical studies. We will focus on early AD, MCI, and cognitively normal older controls. In addition, subjects with non-AD neurodegenerative dementing disorders and Lewy body spectrum disease will be recruited and followed. The Clinical Core jointly with the Education and Information Core will recruit African American AD patients, non-AD dementia patients, MCI, and cognitively normal subjects who are willing to participate in the full range of UW ADRC and ADRC-affiliated clinical research. Clinical Core personnel support and interact with population-based cohorts of late life dementia and normal control subjects appropriate for epidemiologic studies and for accession of normal control postmortem brain tissue. We will continue to collect cerebrospinal fluid (CSF), plasma and serum on these subject samples, and through multi-ADC collaborative efforts, continue to expand the UW ADRC CSF bank to support the search for biomarkers for diagnosis, monitoring disease progression, and identifying asymptomatic persons at risk for dementing disorders. Subjects, biological fluid samples, and data will be provided to meet the research needs of ADRC investigators, the broader UW research community, and investigators at other Institutions.

Public Health Relevance

AD remains an impending public health crisis with no very effective treatments, no cure, and no prevention. This application responds to the need for increased knowledge in AD so that effective treatments can be developed.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005136-30
Application #
8459473
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
30
Fiscal Year
2013
Total Cost
$664,282
Indirect Cost
$71,885
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Tulloch, Jessica; Leong, Lesley; Chen, Sunny et al. (2018) APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement 14:889-894
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Kunji, Khalid; Ullah, Ehsan; Nato Jr, Alejandro Q et al. (2018) GIGI-Quick: a fast approach to impute missing genotypes in genome-wide association family data. Bioinformatics 34:1591-1593
Taylor, Laura M; McMillan, Pamela J; Liachko, Nicole F et al. (2018) Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener 13:7
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Flanagan, Margaret E; Larson, Eric B; Walker, Rod L et al. (2018) Associations between Use of Specific Analgesics and Concentrations of Amyloid-? 42 or Phospho-Tau in Regions of Human Cerebral Cortex. J Alzheimers Dis 61:653-662
Tulloch, Jessica; Leong, Lesley; Thomson, Zachary et al. (2018) Glia-specific APOE epigenetic changes in the Alzheimer's disease brain. Brain Res 1698:179-186
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71

Showing the most recent 10 out of 753 publications